

NANONEUROSCIENCES NEWSLETTER

A YEAR OF INNOVATION - UNLOCKING THE FUTURE OF GLAUCOMA TREATMENT

As we approach the end of 2024, we want to take a moment to reflect on the incredible journey we've embarked on at NanoNeurosciences, Inc. Since our incorporation on February 2024, we've turned our vision into tangible milestones, setting a strong foundation for the future in creating transformative solutions in nanomedicine.

Industry Accolades

Award-Winning Innovation

NanoNeurosciences, Inc. was honored as the **2024 Business of the Year** by the Florida Gainesville Chamber of Commerce, recognizing our commitment to developing groundbreaking medical solutions.



UF Innovate | Accelerate at Sid Martin Biotech Incubator, Alachua, Florida (R&D Laboratories).



Scientific Milestones

Our research team has made significant strides in the past year:

- **Launch of our 1,000-square-foot Research & Development Laboratory:** Featuring state-of-the-art equipment for organic synthesis, chemical purification, biochemistry analysis and sterile human tissue culture experiments.
- **Synthesis of Novel Molecules:** We successfully synthesized our first batch of amphiphilic small molecules, a critical step toward developing a targeted drug delivery system.
- **Nanosphere Technology Development:** We've pioneered innovative nanosphere-forming peptide sequences, enabling precise control over drug release and cellular uptake.
- **Human Tissue Culture Molecular Screenings:** Rigorous molecular screenings have identified promising lead nanoplateforms with high therapeutic potential.

Strategic Partnerships and Business Achievements

To accelerate our progress and maximize our impact, we've forged strategic partnerships with industry leaders:

- o **NVIDIA Collaboration:** We're integrating artificial intelligence into our research, leveraging NVIDIA's advanced computing power to expedite drug discovery.
- o **Manufacturing Partnerships:** Our collaborations with Cambrex and IQVIA as CDMOs will streamline drug development and manufacturing processes and enhance our development capabilities in the U.S. and Europe.
- o **Financial Progress:** We are strategically utilizing the seed funding raised to date to acquire state-of-the-art equipment, including a first-in-class peptide synthesizer. This investment will enhance our capabilities and establish the foundation for pre-clinical testing.
- o **Government Support:** We have submitted a National Science Foundation (NSF), Small Business Innovation Research (SBIR) grant to further propel our research and development.

A Bright Future

Looking ahead to a transformative year, we're filled with optimism and excitement, knowing that together, we've laid the groundwork for cutting-edge and revolutionary advancements in the nanomedicine space for open-angle glaucoma patients.

We're deeply grateful for your trust and support, which inspire us every day to develop innovative solutions and improve the health and lives of millions of people worldwide.

**Thank you for being a part of
our journey!**



Drs. Zois Syrgiannis (left), Salvatore Incontro (middle) and Matias Alvarez-Saavedra (right) inside the NanoNeurosciences laboratory circa December 2024.

The NanoNeurosciences Team

